Last reviewed · How we verify
laropiprant/niacin (MK0524A)
Laropiprant/niacin is a combination of a cholesterol absorption inhibitor and a niacin receptor agonist that works to increase HDL cholesterol and reduce triglycerides.
Laropiprant/niacin is a combination of a cholesterol absorption inhibitor and a niacin receptor agonist that works to increase HDL cholesterol and reduce triglycerides. Used for Hyperlipidemia.
At a glance
| Generic name | laropiprant/niacin (MK0524A) |
|---|---|
| Also known as | MK0524A |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | cholesterol absorption inhibitor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Laropiprant is a selective antagonist of the prostaglandin D2 receptor 1 (DP1), which is involved in the regulation of HDL cholesterol levels. Niacin, on the other hand, acts as a receptor agonist to increase HDL cholesterol and reduce triglycerides. The combination of these two mechanisms of action helps to improve lipid profiles and reduce cardiovascular risk.
Approved indications
- Hyperlipidemia
Common side effects
- Flushing
- Headache
- Nausea
- Dizziness
Key clinical trials
- Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133) (PHASE3)
- MK-0524B Lipid Study (MK-0524B-063) (PHASE3)
- Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143) (PHASE3)
- Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024) (PHASE3)
- A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118) (PHASE3)
- MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED) (PHASE2)
- Lipid Efficacy Study (0524B-022)(COMPLETED) (PHASE3)
- An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- laropiprant/niacin (MK0524A) CI brief — competitive landscape report
- laropiprant/niacin (MK0524A) updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI